IT'S YOUR SKIN

Learn more about TREMFYA®
Kate, Real TREMFYA® Patient

No matter where you are in your TREMFYA® journey, we’re here to help you. The first FDA-approved medication of its kind, TREMFYA® selectively blocks interleukin-23 (IL-23), one of the key proteins thought to be responsible for the symptoms of plaque psoriasis.

Let’s talk about clearer skin

Now that you’ve been prescribed TREMFYA® as a treatment for moderate to severe plaque psoriasis, let us help. Whether you’re waiting to get your prescription filled or are looking for an overview of treatment results seen with TREMFYA® in clinical studies, you’ll find the information you’re looking for here.

UNCOVER CLEARER SKIN

In clinical studies at 16 weeks, at least 7 out of 10 patients with moderate to severe plaque psoriasis saw at least 90% clearer skin and more than 8 out of 10 were rated clear or almost clear.

SUPERIOR SKIN CLEARANCE

In clinical studies, TREMFYA® was proven superior to Humira® (adalimumab) in providing clearer skin.*

PLAQUE PSORIASIS SYMPTOMS

More people using TREMFYA® were free from symptoms, including itching, skin tightness, burning, stinging, and pain at 24 weeks compared with those using Humira®.

STINGING

SKIN TIGHTNESS

ITCHING

BURNING

PAIN

DOSING PROFLE

TREMFYA® is given as a single 100 mg injection under your skin once every 8 weeks, after 2 starter doses at weeks 0 and 4. That means you don’t have to think about your next scheduled maintenance dose for almost two months between injections.

FIRST 52 WEEKS OF THERAPY